Crohn's disease (CD) accounts for a variety of clinical manifestations or phenotypes that
stem from chronic inflammation in the gastrointestinal tract. Its worldwide incidence is …

The emergence of novel immunomodulatory cancer therapies over the last decade, above
all immune checkpoint blockade, has significantly advanced tumor treatment. For colorectal …

This guideline is the second European Crohn's and Colitis Organisation [ECCO] evidence-
based consensus on inflammatory bowel disease [IBD] and malignancy, and is an update …

The global prevalence of cancer is increasing, largely as more patients are living into old
age. Therefore, gastroenterologists caring for patients with inflammatory bowel disease [IBD] …

The risk of colorectal cancer for any patient with ulcerative colitis is known to be elevated,
and is estimated to be 2% after 10 years, 8% after 20 years and 18% after 30 years of …

BACKGROUND & AIMS: Although anti–tumor necrosis factor (TNF) therapy can effectively
treat Crohn's disease (CD), there is concern that it might increase the risk of non-Hodgkin's …

Background & Aims: We performed a meta-analysis of placebo-controlled trials to evaluate
safety and efficacy of tumor necrosis factor (TNF) antagonists for Crohn's disease. Methods …

Crohn disease and ulcerative colitis are chronic inflammatory bowel diseases (IBD)
characterized by recurrent episodes of mucosal inflammation. This chronic mucosal …

Background and aims: This study evaluates the long-term safety of infliximab in patients with
inflammatory bowel disease (IBD) treated with the drug over a 14-year period. Methods: The …

OBJECTIVES: The objective of this study was to analyze the safety of long-term infliximab
treatment, with/without concomitant immunomodulators, across Crohn's disease (CD) and …